Literature DB >> 22009724

Heparanase is highly expressed and regulates proliferation in GH-secreting pituitary tumor cells.

Hadara Rubinfeld1, Victoria Cohen-Kaplan, Dvora Nass, Neta Ilan, Shilhav Meisel, Zvi R Cohen, Moshe Hadani, Israel Vlodavsky, Ilan Shimon.   

Abstract

Pituitary tumorigenesis involves remodeling of the extracellular matrix (ECM). Heparanase, an endoglycosidase capable of degrading heparan sulfate, a major polysaccharide constituent of the ECM, is implicated in diverse processes associated with ECM remodeling, such as morphogenesis, angiogenesis, and tumor invasion. The aim of this study was to investigate the possible role of heparanase in pituitary tumorigenesis. Human normal pituitaries and pituitary tumors were examined for heparanase mRNA and protein expression using real-time PCR and immunohistochemistry, respectively. Cell proliferation was assessed by colony formation after heparanase overexpression in GH3 and MtT/S cells. Cell viability and cell cycle progression were evaluated after heparanase gene silencing. Higher heparanase mRNA and protein expression was noted in GH tumors as compared with normal pituitaries. Heparanase overexpression in GH3 and MtT/S cells resulted in a 2- to 3-fold increase in colony number, compared with control cells. Cell viability decreased by 50% after heparanase gene silencing due to induced apoptosis reflected by increased fraction of cleaved poly-ADP-ribose polymerase and sub-G1 events. Notably, exogenously added heparanase enhanced epidermal growth factor receptor, Src, Akt, ERK, and p38 phosphorylation in pituitary tumor cells. Our results indicate that heparanase enhances pituitary cell viability and proliferation and may thus contribute to pituitary tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009724     DOI: 10.1210/en.2011-0273

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Astragalus embranaceus extract activates immune response in macrophages via heparanase.

Authors:  Qiaojing Qin; Jianying Niu; Zhaoxia Wang; Wangjie Xu; Zhongdong Qiao; Yong Gu
Journal:  Molecules       Date:  2012-06-13       Impact factor: 4.411

Review 2.  Heparanase and the hallmarks of cancer.

Authors:  Krishnath M Jayatilleke; Mark D Hulett
Journal:  J Transl Med       Date:  2020-11-30       Impact factor: 5.531

3.  Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway.

Authors:  Qiaojing Qin; Jianying Niu; Zhaoxia Wang; Wangjie Xu; Zhongdong Qiao; Yong Gu
Journal:  Cardiovasc Diabetol       Date:  2013-02-26       Impact factor: 9.951

4.  Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.

Authors:  Amit Katz; Uri Barash; Ilanit Boyango; Sari Feld; Yaniv Zohar; Edward Hammond; Neta Ilan; Ran Kremer; Israel Vlodavsky
Journal:  Oncotarget       Date:  2018-04-10

Review 5.  Heparanase, cell signaling, and viral infections.

Authors:  Raghuram Koganti; Rahul Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2020-05-27       Impact factor: 9.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.